Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu

Cambridge BioMarketing

March 2015

Petsky Prunier advises Cambridge BioMarketing on its sale to Everyday Health

March 27, 2015 (New York, NY) – Petsky Prunier is pleased to announce it has advised Cambridge BioMarketing Group, LLC, the leader in strategic launch and marketing solutions for orphan and rare disease products, on its sale to Everyday Health, Inc. (NYSE: EVDY), a leader in digital health and wellness solutions.

The acquisition of Cambridge BioMarketing will broaden Everyday Health’s strategic marketing and communications solutions to pharmaceutical brands targeting the orphan and rare disease segments of the market. The orphan and rare disease market is estimated to grow from $90 billion in 2013 to $176 billion by 2020, accounting for approximately 19% of all branded-drug sales by 2020, up from approximately 9% percent in 2006. Commercializing in markets with small global patient populations requires sophisticated and highly targeted digital marketing capabilities. For existing Cambridge BioMarketing clients, the acquisition will add to the company's digital analytic, executional, and strategic services focused on these unique populations, while increasing access and visibility across a wide range of media channels.

Everyday Health intends to utilize its existing audience, content, and data assets to enable Cambridge BioMarketing's customers to directly engage with consumers and healthcare professionals, as well as to provide more robust content offerings focused on orphan and rare diseases. For example, Everyday Health's MedPage Today news platform will better educate physicians on the treatment of rare and orphan diseases and directly connect them with other healthcare professionals that treat these patients. Likewise, Everyday Health, through its existing relationship with MayoClinic.org, will leverage their premier content and tools focused on rare and orphan diseases.

Cambridge BioMarketing has approximately 70 employees with extensive clinical, creative, digital strategy, and pharmaceutical marketing expertise that spans multiple stages of development and audiences ranging from patients to physicians to payors. Cambridge BioMarketing’s CEO Maureen Franco will continue to lead the Cambridge BioMarketing business together with the existing management team.

A team from Petsky Prunier, led by Christopher French and John Prunier, served as exclusive financial advisor to Cambridge BioMarketing Group.

ADDITIONAL RESOURCES:

How can we help?

If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.

Back to top